Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 122

1.

Ponatinib evaluation and safety in real-life chronic myelogenous leukemia patients failing more than two tyrosine kinase inhibitors: the PEARL observational study.

Heiblig M, Rea D, Chrétien ML, Charbonnier A, Rousselot P, Coiteux V, Escoffre-Barbe M, Dubruille V, Huguet F, Cayssials E, Hermet E, Guerci-Bresler A, Amé S, Sackmann-Sala L, Roy L, Sobh M, Morisset S, Etienne G, Nicolini FE.

Exp Hematol. 2018 Nov;67:41-48. doi: 10.1016/j.exphem.2018.08.006. Epub 2018 Sep 5.

PMID:
30195076
2.

Ponatinib: A new tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia.

Shamroe CL, Comeau JM.

Ann Pharmacother. 2013 Nov;47(11):1540-6. doi: 10.1177/1060028013501144. Epub 2013 Nov 21. Review.

PMID:
24265264
3.

A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias.

Cortes JE, Kim DW, Pinilla-Ibarz J, le Coutre P, Paquette R, Chuah C, Nicolini FE, Apperley JF, Khoury HJ, Talpaz M, DiPersio J, DeAngelo DJ, Abruzzese E, Rea D, Baccarani M, Müller MC, Gambacorti-Passerini C, Wong S, Lustgarten S, Rivera VM, Clackson T, Turner CD, Haluska FG, Guilhot F, Deininger MW, Hochhaus A, Hughes T, Goldman JM, Shah NP, Kantarjian H; PACE Investigators.

N Engl J Med. 2013 Nov 7;369(19):1783-96. doi: 10.1056/NEJMoa1306494. Epub 2013 Nov 1.

4.
5.

A personalised medicine approach for ponatinib-resistant chronic myeloid leukaemia.

Korfi K, Mandal A, Furney SJ, Wiseman D, Somervaille TC, Marais R.

Ann Oncol. 2015 Jun;26(6):1180-7. doi: 10.1093/annonc/mdv110. Epub 2015 Feb 23.

6.

The impact of multiple low-level BCR-ABL1 mutations on response to ponatinib.

Parker WT, Yeung DT, Yeoman AL, Altamura HK, Jamison BA, Field CR, Hodgson JG, Lustgarten S, Rivera VM, Hughes TP, Branford S.

Blood. 2016 Apr 14;127(15):1870-80. doi: 10.1182/blood-2015-09-666214. Epub 2016 Jan 14.

7.

Life after ponatinib failure: outcomes of chronic and accelerated phase CML patients who discontinued ponatinib in the salvage setting.

Boddu P, Shah AR, Borthakur G, Verstovsek S, Garcia-Manero G, Daver N, Kadia T, Ravandi F, Jain N, Alhuraiji A, Burger J, Kornblau S, Pierce S, Dellasala S, Jabbour E, Kantarjian H, Cortes J.

Leuk Lymphoma. 2018 Jun;59(6):1312-1322. doi: 10.1080/10428194.2017.1379076. Epub 2017 Oct 3.

8.

Ponatinib in refractory Philadelphia chromosome-positive leukemias.

Cortes JE, Kantarjian H, Shah NP, Bixby D, Mauro MJ, Flinn I, O'Hare T, Hu S, Narasimhan NI, Rivera VM, Clackson T, Turner CD, Haluska FG, Druker BJ, Deininger MW, Talpaz M.

N Engl J Med. 2012 Nov 29;367(22):2075-88. doi: 10.1056/NEJMoa1205127.

9.

Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: final 5-year results of the phase 2 PACE trial.

Cortes JE, Kim DW, Pinilla-Ibarz J, le Coutre PD, Paquette R, Chuah C, Nicolini FE, Apperley JF, Khoury HJ, Talpaz M, DeAngelo DJ, Abruzzese E, Rea D, Baccarani M, Müller MC, Gambacorti-Passerini C, Lustgarten S, Rivera VM, Haluska FG, Guilhot F, Deininger MW, Hochhaus A, Hughes TP, Shah NP, Kantarjian HM.

Blood. 2018 Jul 26;132(4):393-404. doi: 10.1182/blood-2016-09-739086. Epub 2018 Mar 22.

10.

Ponatinib in chronic myeloid leukemia (CML): Consensus on patient treatment and management from a European expert panel.

Müller MC, Cervantes F, Hjorth-Hansen H, Janssen JJWM, Milojkovic D, Rea D, Rosti G.

Crit Rev Oncol Hematol. 2017 Dec;120:52-59. doi: 10.1016/j.critrevonc.2017.10.002. Epub 2017 Oct 8. Review.

11.

Overall survival with ponatinib versus allogeneic stem cell transplantation in Philadelphia chromosome-positive leukemias with the T315I mutation.

Nicolini FE, Basak GW, Kim DW, Olavarria E, Pinilla-Ibarz J, Apperley JF, Hughes T, Niederwieser D, Mauro MJ, Chuah C, Hochhaus A, Martinelli G, DerSarkissian M, Duh MS, McGarry LJ, Kantarjian HM, Cortes JE.

Cancer. 2017 Aug 1;123(15):2875-2880. doi: 10.1002/cncr.30558. Epub 2017 Apr 7.

12.

Ponatinib--a step forward in overcoming resistance in chronic myeloid leukemia.

Frankfurt O, Licht JD.

Clin Cancer Res. 2013 Nov 1;19(21):5828-34. doi: 10.1158/1078-0432.CCR-13-0258. Epub 2013 Aug 9. Review.

13.

The role of ponatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia.

Sanford DS, Kantarjian H, O'Brien S, Jabbour E, Cortes J, Ravandi F.

Expert Rev Anticancer Ther. 2015 Apr;15(4):365-73. doi: 10.1586/14737140.2015.1025256. Epub 2015 Mar 12. Review.

PMID:
25764322
14.

Ponatinib for the treatment of chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia.

Narayanan V, Pollyea DA, Gutman JA, Jimeno A.

Drugs Today (Barc). 2013 Apr;49(4):261-9. doi: 10.1358/dot.2013.49.4.1950147. Review.

PMID:
23616953
15.

Ponatinib in the treatment of chronic myeloid leukemia and philadelphia chromosome positive acute lymphoblastic leukemia.

Pavlovsky C, Chan O, Talati C, Pinilla-Ibarz J.

Future Oncol. 2019 Jan;15(3):257-269. doi: 10.2217/fon-2018-0371. Epub 2018 Sep 25. Review.

PMID:
30251548
16.

Ponatinib: a third-generation inhibitor for the treatment of CML.

Wehrle J, Pahl HL, von Bubnoff N.

Recent Results Cancer Res. 2014;201:99-107. doi: 10.1007/978-3-642-54490-3_5. Review.

PMID:
24756787
17.

Ponatinib: A Third-Generation Inhibitor for the Treatment of CML.

Wehrle J, von Bubnoff N.

Recent Results Cancer Res. 2018;212:109-118. doi: 10.1007/978-3-319-91439-8_5.

PMID:
30069627
18.

Ponatinib versus imatinib for newly diagnosed chronic myeloid leukaemia: an international, randomised, open-label, phase 3 trial.

Lipton JH, Chuah C, Guerci-Bresler A, Rosti G, Simpson D, Assouline S, Etienne G, Nicolini FE, le Coutre P, Clark RE, Stenke L, Andorsky D, Oehler V, Lustgarten S, Rivera VM, Clackson T, Haluska FG, Baccarani M, Cortes JE, Guilhot F, Hochhaus A, Hughes T, Kantarjian HM, Shah NP, Talpaz M, Deininger MW; EPIC investigators.

Lancet Oncol. 2016 May;17(5):612-21. doi: 10.1016/S1470-2045(16)00080-2. Epub 2016 Apr 12.

PMID:
27083332
19.

Ponatinib (Iclusig) for CML and Ph+ ALL.

[No authors listed]

Med Lett Drugs Ther. 2013 Sep 2;55(1424):71-2. Review. No abstract available.

PMID:
25970013
20.

Causes of resistance and treatment choices of second- and third-line treatment in chronic myelogenous leukemia patients.

Hochhaus A, Ernst T, Eigendorff E, La Rosée P.

Ann Hematol. 2015 Apr;94 Suppl 2:S133-40. doi: 10.1007/s00277-015-2323-1. Epub 2015 Mar 27. Review.

PMID:
25814079

Supplemental Content

Support Center